The online version of this article (doi:10.1186/1477-7819-10-246) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
C-NY participated in the design and coordination of the study and helped to draft the manuscript; T-LH, C-SH, P-HL, C-WW, KC-G, Y-YJ and M-FC reviewed the manuscript and provided revisions. All authors have read and approved the final manuscript.
For many years, the understanding of gastrointestinal stromal tumors (GISTs), which are the most common mesenchymal tumors of the gastrointestinal tract, has been very limited. However, it is now possible to provide a more precise definition through the use of pathology classification and molecular techniques. Coupled with the advancement of clinical practice, especially the development of targeted therapy, there is now a much better insight into its treatment. At present, organizations such as the National Comprehensive Cancer Network in the USA and the European Society for Medical Oncology in Europe have established a consensus and drawn up guidelines for the diagnosis, treatment, and follow-up of GISTs.
With experts coming from various districts in Taiwan and combining the most recent clinical data and experiences, the Taiwan Surgical Society of Gastroenterology drafted the first national GIST treatment guidelines after a consensus meeting in 2007. Following subsequent advances in GIST diagnosis and treatment, further revisions and modifications have been made to the original guidelines. We present here the updated consensus and recommendations of the Taiwan Surgical Society of Gastroenterology for the diagnosis and treatment of GIST. We hope these guidelines can help enhance the quality of diagnosis, treatment, and care of patients with GIST in Taiwan.
Demetri GD, Benjamin RS, Blanke CD: NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007, 5 (suppl 2): S1-S29. PubMed
von Mehren M, Benjamin RS, Bui MM: Soft tissue sarcoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012, 1;10 (8): 951-960.
Casali PG, Jost L, Reichardt P: Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009, 20 (suppl 4): 64-67. PubMed
Miettinen M, Lasota J: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006, 130: 1466-1478. PubMed
Choi H, Charnsangavej C, Faria SC: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007, 25: 1753-1759. 10.1200/JCO.2006.07.3049. CrossRefPubMed
DeMatteo RP, Owzar K, Antonescu CR: Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000. 2008, Orlando, Florida: Abstract 8; presented at the 2008 ASCO Gastrointestinal Cancers Symposium, 25-27.
Blanke CD, Demetri GD, von Mehren M: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008, 26: 620-625. 10.1200/JCO.2007.13.4403. CrossRefPubMed
Blanke CD, Rankin C, Demetri GD: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008, 26: 626-632. 10.1200/JCO.2007.13.4452. CrossRefPubMed
Eisenberg BL, Harris J, Blanke CD: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009, 99: 42-47. 10.1002/jso.21160. PubMedCentralCrossRefPubMed
- Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan
- BioMed Central
Neu im Fachgebiet Chirurgie
Mail Icon II